In vivo study on the effectiveness of a lacquer containing CaF2/NaF in treating dentine hypersensitivity.
The purpose of this double-blind study was to evaluate the effectiveness of a commercially available fluoride lacquer (Bifluorid 12) containing CaF2 (6%) and NaF (6%) in reducing dentine hypersensitivity. A fluoride lacquer containing only NaF (6%) served as a control. Twenty-five adult patients complaining about at least two hypersensitive teeth participated in this study. In each patient and at each appointment, one tooth was treated with Bifluorid 12, while the other was treated with the control substance. Sensitivity levels were determined before and after the application of each lacquer at baseline as well as at 1, 2 and 3 weeks after the start of study. The final evaluation of hypersensitivity was performed at 4 weeks, and follow-ups were undertaken at 6 and 12 months. A reproducible air blast stimulus and a visual analogue scale were used for evaluation. Results demonstrated a distinct reduction of hypersensitivity after 1, 2 and 3 weeks in the Bifluorid 12 group. Initially, no obvious effects could be observed in the control group. However, a clear alleviation could be observed after 2 and 3 weeks with the control. After 4 weeks, the overall sensitivity scores were comparably low, without any significant differences between the two fluoride lacquers. In both groups, the effects of treatment were seen over the 12-month observation period. Bifluorid 12 was considered at least comparable to the control. It is concluded from this study that Bifluorid 12 is effective in the initial reduction of dentine hypersensitivity. The combination of CaF2/NaF can be recommended for clinical use.
Kielbassa
A M
AM
Department of Operative Dentistry, School of Dental Medicine, Albert-Ludwigs-University of Freiburg, Germany. kielbass@zmkz.ukl.uni-freiburg.de
Attin
T
T
Hellwig
E
E
Schade-Brittinger
C
C
D000328:Adult; D002124:Calcium Fluoride / Q000627:therapeutic use*; D003807:Dentin Sensitivity / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005460:Fluorides, Topical / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D012969:Sodium Fluoride / Q000627:therapeutic use*; D018709:Statistics, Nonparametric
C094502:Bifluorid 12; D005460:Fluorides, Topical; D012969:Sodium Fluoride; D002124:Calcium Fluoride